CRISPR

CRISPR1-lipf

ID
ZDB-CRISPR-211116-3
Name
CRISPR1-lipf
Previous Names
None
Target
Sequence
5' - GGTAATACTTACATCTGGAC - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genome Build: GRCz11Chromosome: 12
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
ecn5 lipf
Expression
Gene expression in Wild Types + CRISPR1-lipf
No data available
Phenotype
Phenotype resulting from CRISPR1-lipf
No data available
Phenotype of all Fish created by or utilizing CRISPR1-lipf
Phenotype Fish Conditions Figures
liver map1lc3b expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver atg4a expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver pnpla2 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver tfeb expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
whole organism triglyceride decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver casp9 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver gadd45aa expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
hepatocyte lipid droplet increased size, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 6 from Han et al., 2021
liver sqstm1 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver ulk1a expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver lipeb expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
whole organism icosapentaenoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver becn1 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver sqstm1 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver il6 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
liver map1lc3b expression decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver atg7 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver fatty acid decreased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 6 from Han et al., 2021
whole organism oxygen metabolic process decreased magnitude, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
whole organism octanoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver lipea expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver lamp1b expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver atf6 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: 3-methyladenine Fig. 8 from Han et al., 2021
liver abhd5a expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
whole organism nonadecanoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver lipf expression decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
whole organism decreased weight, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 6 from Han et al., 2021
liver atg5 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver mt-atp6 expression decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
liver mt-cyb expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
whole organism tetradecanoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver plin2 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver mgll expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver cholesterol increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 6 from Han et al., 2021
liver ssbp1 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver casp3a expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
whole organism docosahexaenoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver xbp1 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: 3-methyladenine Fig. 8 from Han et al., 2021
liver plin1 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver pnpla2 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver tfam expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver atg12 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
whole organism icosanoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
whole organism decanoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
whole organism protein decreased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 6 from Han et al., 2021
liver low-density lipoprotein increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 6 from Han et al., 2021
liver map1lc3b expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver ddit3 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
liver ulk1b expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver cholesterol increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 6 from Han et al., 2021
liver tnfa expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver vacuolated, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver ddit3 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver mt-atp6 expression amount, ameliorated lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver ulk1b expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
whole organism protein decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2,  Fig. 6 from Han et al., 2021
whole organism phosphatidylcholine increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver lamp1b expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7,  Fig. 8 from Han et al., 2021
whole organism phosphatidylethanolamine increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
whole organism hexadecenoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
whole organism decreased weight, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2,  Fig. 6 from Han et al., 2021
liver mgll expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
whole organism docosanoic acid decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver atg4a expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
whole organism lipid decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2,  Fig. 6 from Han et al., 2021
liver gadd45aa expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver yellow, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
hepatocyte mitochondrion increased size, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver tfeb expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver il1b expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
liver plin2 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver cav1 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver fatty acid decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 6 from Han et al., 2021
liver atg7 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver abhd5a expression amount, ameliorated lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
whole organism linoleic acid decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver lipf expression decreased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver vacuole increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver mt-nd1 expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 8 from Han et al., 2021
whole organism pentadecanoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
liver tnfa expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
liver casp9 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
liver tfam expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
liver map1lc3b expression amount, ameliorated lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver becn1 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver cav1 expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 7 from Han et al., 2021
liver low-density lipoprotein increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 6 from Han et al., 2021
liver lipea expression increased amount, abnormal lipfecn5/ecn5 (AB) chemical treatment by diet: inhibitor Fig. 7 from Han et al., 2021
liver il1b expression increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 8 from Han et al., 2021
swimming decreased linear velocity, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
whole organism elaidic acid decreased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
whole organism (15Z)-tetracosenoic acid increased amount, abnormal lipfecn5/ecn5 (AB) standard conditions Fig. 2 from Han et al., 2021
Citations
No data available
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.